表紙
市場調查報告書
商品編碼
1036269

全基因組和外顯子組測序市場:按使用、按有機體、按產品(2022-2026)

WHOLE GENOME and EXOME SEQUENCING MARKETS, By Application, Organism and Product with Executive and Consultant Guides. Includes Direct to Consumer Analysis. 2022 to 2026 "

出版日期: | 出版商: Howe Sound Research | 英文 596 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介
本報告探討了全基因組和外顯子組測序的全球市場,提供了市場概況、應用、生物體和產品的趨勢,以及進入市場的公司概況。

目錄

第 1 章市場指南

  • 全基因組測序市場-戰略態勢邏輯和 COVID 的影響
  • 高管、營銷、銷售和業務發展人員指南
  • 管理顧問和投資顧問指南

第二章市場的介紹和定義

  • 本報告中全基因組測序的定義
  • 基因組學革命
  • 市場定義
  • 展望:醫療保健、IVD 行業和 COVID-19 大流行
  • 基因組大小
  • 基於安裝的高通量測序設施列表

第 3 章市場概覽

  • 市場參與者扮演各種角色
    • 設備製造商
    • 專業/獨立實驗室
    • 獨立的國家/地區實驗室
    • 獨立實驗室分析
    • 公共國家/地區研究所
    • 醫院實驗室
    • 臨床實驗室
    • DTC 實驗室
    • 測序實驗室
    • 審計機構
  • 全基因組測序-市場、例子、討論
  • 產業結構

第 4 章市場趨勢

  • 生長促進劑
    • 診斷因素
    • 代碼解釋
    • 農業的變化
    • 生育治療技術時代
    • 病原體問題
  • 生長抑製劑
    • 競爭加劇導致價格下降
    • 低成本
    • 醫療成本問題抑制增長
    • 健康的缺點
    • 轉基因反對運動
  • 測序裝置

第 5 章 WGES 的最新發展

第六章主要公司簡介

  • 10x Genomics, Inc.
  • 23andME Inc.
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Agena Bioscience, Inc.
  • Agilent
  • Akonni Biosystems
  • Ancestry.com LLC
  • Anchor Dx
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioM?rieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • C2i Genomics
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Centogene
  • Chronix Biomedical
  • Circulogene
  • Clear Labs
  • Clinical Genomics
  • Complete Genomics, Inc.-A BGI Company
  • Cynvenio
  • Dante Labs
  • Datar Cancer Genetics Limited
  • Day Zero Diagnostics
  • Diasorin S.p.A.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Excellerate Bioscience
  • Exosome Diagnostics
  • Fabric Genomics
  • Fluidigm Corp
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • Fulgent Genetics
  • GE Global Research
  • GE Healthcare Life Sciences
  • Gencove
  • Genedrive
  • GeneFirst Ltd.
  • Genetron Health(Beijing)Co., Ltd.
  • Genewiz
  • Genomic Health
  • Genomics England
  • Genomics Personalized Health(GPH)
  • GenomOncology
  • Genzyme Corporation
  • Grail, Inc.
  • Grifols
  • Guardant Health
  • Guardiome
  • HeiScreen
  • Helix
  • Helomics
  • Hologic
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • Human Longevity, Inc.
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivoscribe
  • Karius
  • Macrogen
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Medgenome
  • Meridian Bioscience
  • Mesa Biotech
  • MIODx
  • miR Scientific
  • MNG Labs
  • Molecular MD
  • NantHealth, Inc.
  • Natera
  • Nebula Genomics
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Omega Bioservices
  • OncoDNA
  • OpGen
  • ORIG3N, Inc.
  • Origene Technologies
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Protagen Diagnostics
  • Qiagen Gmbh
  • Quantumdx
  • Regeneron
  • Roche Molecular Diagnostics
  • Roswell Biotechnologies
  • Seegene
  • Sequencing.com
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SkylineDx
  • Stratos Genomics
  • Sure Genomics, Inc.
  • Sysmex
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Veritas Genetics
  • Volition

第 7 章全球基因組和外顯子組測序市場

  • 按國家/地區分列的世界市場概覽
  • 世界市場概覽,按應用
  • 世界市場概覽,按生物體
  • 全球市場概覽,按產品

第 8 章全球基因組和外顯子組測序市場-按用途

  • 研究
  • 臨床實踐中的人類
  • 臨床腫瘤
  • 臨床病原體
  • D2C
  • 農業/其他

第 9 章全球基因組和外顯子組測序市場-按生物體

  • 人類
  • 病原體
  • 其他

第 10 章全球基因組和外顯子組測序市場-副產品

  • 設備
  • 試劑
  • 分析
  • 軟件及其他

第 11 章全基因組和外顯子組測序的未來願景

第 12 章附錄

目錄

OVERVIEW:

The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer related activity has suffered. Find out all about it in the comprehensive report of Whole Genome Sequencing. The complete genome of the COVID virus is included as an example of the work being done.

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?

Our facts and support = Your success.

A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

All report data is available in Excel format on request. Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Whole Genome Sequencing Market - Strategic Situation Analysis & COVID Impact
    • 1.1.1 Selected Genetic Testing Companies Revenue & Growth
    • 1.1.2 Selected Companies Growth Chart
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 Whole Genome Sequencing Definition In This Report
    • 2.1.1 Whole and Exome Sequencing
    • 2.1.2 Research and Clinical
    • 2.1.3 Clinical Tumor
    • 2.1.4 Clinical Pathogen
    • 2.1.5 Agri/Other
    • 2.1.6 Direct to Consumer
  • 2.2 The Genomics Revolution
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.4.1 Global Healthcare Spending
    • 2.4.2 Spending on Diagnostics
    • 2.4.3 Important Role of Insurance for Diagnostics
  • 2.5 Sizing the Genome - Not What You Think
    • 2.5.1 Cost, Price and Genome Size, Pricing Practice
  • 2.6 GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts

3 Market Overview

  • 3.1 Market Participants Play Different Roles
    • 3.1.1 Instrument Manufacturer
    • 3.1.2 Independent lab specialized/esoteric
    • 3.1.3 Independent lab national/regional
    • 3.1.4 Independent lab analytical
    • 3.1.5 Public National/regional lab
    • 3.1.6 Hospital lab
    • 3.1.7 Physician lab
    • 3.1.8 DTC Lab
    • 3.1.9 Sequencing Labs
    • 3.1.10 Audit body
  • 3.2 Whole Genome Sequencing -Markets, Examples and Discussion
    • 3.2.1 Direct to Consumer - Two Approaches
      • 3.2.1.1 The New Age of Medical Information
      • 3.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
      • 3.2.1.3 Newborn and Prenatal - A Brave New World
      • 3.2.1.4 DTC - How Many Segments?
    • 3.2.2 Research Markets
      • 3.2.2.1 Research Funding and Capital Expense
      • 3.2.2.2 WGS Datasets Preferred
      • 3.2.2.3 Existing research repurposed
      • 3.2.2.4 Organism Wide Market
      • 3.2.2.5 Service Suppliers Respond
    • 3.2.3 Clinical - Understanding Germline and Somatic
      • 3.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
    • 3.2.4 Pathogen Testing
      • 3.2.4.1 The Hepatitis C Story
      • 3.2.4.2 Will the Microbiology Department Disappear?
    • 3.2.5 AgriBio - Big Business
      • 3.2.5.1 GMO is Here to Stay
      • 3.2.5.2 WGS Benefits and Risks
      • 3.2.5.3 The New Agriculture
  • 3.3 Industry Structure
    • 3.3.1 Hospital's Testing Share
    • 3.3.2 Economies of Scale
    • 3.3.3 Instrument Manufacturer Role
    • 3.3.4 Healthcare Industry Impacts - Still Struggling
      • 3.3.4.1 Can the Healthcare Industry Adapt?
      • 3.3.4.2 Genetic Counselling as an Industry
      • 3.3.4.3 WGES Adoption and Cannibalization
      • 3.3.4.4 The Meaning of Grail

4 Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Diagnostic Factors
    • 4.1.2 Interpreting the Code Otherwise
    • 4.1.3 Changes in Agriculture
    • 4.1.4 Fertility Technology Comes of Age
    • 4.1.5 Pathogen Challenges
  • 4.2 Factors Limiting Growth
    • 4.2.1 Increased Competition Lowers Price
    • 4.2.2 Lower Costs
    • 4.2.3 Healthcare Cost Concerns Curtail Growth
    • 4.2.4 Wellness has a downside
    • 4.2.5 GMO Opposition Movement
  • 4.3 Sequencing Instrumentation
    • 4.3.1 Instrumentation Tenacity
    • 4.3.2 Declining Cost Changes Industry Structure
    • 4.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS
    • 4.3.4 Illumina
    • 4.3.5 ION
    • 4.3.6 Pacific Biosystems
    • 4.3.7 Roche 454
    • 4.3.8 SOLiD
    • 4.3.9 Oxford Nanopore
      • 4.3.9.1 What is Oxford Nanopore Sequencing?
      • 4.3.9.2 What can Oxford Nanopore Sequencingt be used for?
      • 4.3.9.3 Oxford Nanopore Products
    • 4.3.10 Long Reads - Further Segmentation
    • 4.3.11 Linked Reads
    • 4.3.12 Targeted Sequencing Adopts CRISPR
    • 4.3.13 New Sequencing Technologies
      • 4.3.13.1 RNAP sequencing
      • 4.3.13.2 In vitro virus high-throughput sequencing
      • 4.3.13.3 Tunnelling currents DNA sequencing
      • 4.3.13.4 Sequencing by hybridization
      • 4.3.13.5 Sequencing with mass spectrometry
      • 4.3.13.6 Microfluidic Sanger sequencing
      • 4.3.13.7 Microscopy-based techniques

5 WGES Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.2 GenomSys Gains CE Mark for New Genomic Analysis Software
  • 5.3 WGS Finds Lung Cancers Fall Into Molecular Subtypes
  • 5.4 Testing Distinguishes Benign Tumors From Precancerous Condition
  • 5.5 Plan to Sequence All Newborns in UK
  • 5.6 Clear Labs Raises $60M for Nanopore Sequencing
  • 5.7 Variantyx Expands Into Prenatal, Cancer Testing
  • 5.8 Whole-Genome Sequencing Aids Diagnosis in Stockholm
  • 5.9 Variantyx Raises $20M
  • 5.10 Nonacus WGS Service for SARS-CoV-2 Laboratories
  • 5.11 Center to Report Risk Scores in Clinical WGS
  • 5.12 Stanford Launches WGS for Cardiovascular Testing
  • 5.13 Illumina and NY Healthcare Partner on Clinical WGS
  • 5.14 Increased Adoption of WGS Needs Acceptance by Payors, Providers
  • 5.15 Veritas Intercontinental Completes €5M Series B Financing Round
  • 5.16 M2GEN and Discovery Life Sciences in Bioinformatics Agreement
  • 5.17 Genomics England Adopts Quantum ActiveScale Object Storage
  • 5.18 GenomiQa, Icon Group to Validate Genomic Analysis Platform CapeDx
  • 5.19 NHS Wales Introduces WGS for Critically Ill Newborns
  • 5.20 Illumina Achieves EAU for NGS-Based SARS-CoV-2 Test
  • 5.21 C2i Genomics to Launch Trials for MRD Detection Tech
  • 5.22 Roche Acquires Sequencing Company Stratos Genomics
  • 5.23 UK COVID-19 Sequencing Consortium Launches
  • 5.24 Invitae Acquires Three Companies: YouScript, Genelex, Diploid
  • 5.25 Experience From Centralized Genomic Medicine Lab
  • 5.26 MGI to Enable $100 Human Genome
  • 5.27 Nebula Genomics offers $299 WGS
  • 5.28 Team to Study Campylobacter Omics
  • 5.29 Veritas Genetics Restarts US Business
  • 5.30 NEOGEN, Gencove partner to advance animal genomics
  • 5.31 UK Whole-Genome Sequencing Project Obtains £200M
  • 5.32 WGS may help with disease outbreaks
  • 5.33 Veritas Cuts WGS Price by 40%
  • 5.34 Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing
  • 5.35 Machine-learning system used to diagnose genetic diseases
  • 5.36 Whole Genome Sequencing for healthy creates controversy
  • 5.37 Nebula Genomics Offers FREE Whole Genome Sequencing

6 Profiles of Key Companies

  • 6.1 10x Genomics, Inc.
  • 6.2 23andME Inc.
  • 6.3 Abbott Diagnostics
  • 6.4 AccuraGen Inc.
  • 6.5 Adaptive Biotechnologies
  • 6.6 Admera Health, LLC
  • 6.7 Agena Bioscience, Inc.
  • 6.8 Agilent
  • 6.9 Akonni Biosystems
  • 6.10 Ancestry.com LLC
  • 6.11 Anchor Dx
  • 6.12 ArcherDx, Inc.
  • 6.13 ARUP Laboratories
  • 6.14 Asuragen
  • 6.15 Baylor Miraca Genetics Laboratories
  • 6.16 Beckman Coulter Diagnostics
  • 6.17 Becton, Dickinson and Company
  • 6.18 BGI Genomics Co. Ltd
  • 6.19 Bioarray Genetics
  • 6.20 Biocept, Inc.
  • 6.21 Biodesix Inc.
  • 6.22 BioFluidica
  • 6.23 BioGenex
  • 6.24 Biolidics Ltd
  • 6.25 bioMérieux Diagnostics
  • 6.26 Bioneer Corporation
  • 6.27 Bio-Rad Laboratories, Inc
  • 6.28 Bio-Techne
  • 6.29 C2i Genomics
  • 6.30 Cancer Genetics
  • 6.31 Caris Molecular Diagnostics
  • 6.32 CellMax Life
  • 6.33 Centogene
  • 6.34 Chronix Biomedical
  • 6.35 Circulogene
  • 6.36 Clear Labs
  • 6.37 Clinical Genomics
  • 6.38 Complete Genomics, Inc. - A BGI Company
  • 6.39 Cynvenio
  • 6.40 Dante Labs
  • 6.41 Datar Cancer Genetics Limited
  • 6.42 Day Zero Diagnostics
  • 6.43 Diasorin S.p.A.
  • 6.44 Epic Sciences
  • 6.45 Epigenomics AG
  • 6.46 Eurofins Scientific
  • 6.47 Excellerate Bioscience
  • 6.48 Exosome Diagnostics
  • 6.49 Fabric Genomics
  • 6.50 Fluidigm Corp
  • 6.51 Freenome
  • 6.52 FUJIFILM Wako Diagnostics
  • 6.53 Fujirebio
  • 6.54 Fulgent Genetics
  • 6.55 GE Global Research
  • 6.56 GE Healthcare Life Sciences
  • 6.57 Gencove
  • 6.58 Genedrive
  • 6.59 GeneFirst Ltd.
  • 6.60 Genetron Health (Beijing) Co., Ltd.
  • 6.61 Genewiz
  • 6.62 Genomic Health
  • 6.63 Genomics England
  • 6.64 Genomics Personalized Health (GPH)
  • 6.65 GenomOncology
  • 6.66 Genzyme Corporation
  • 6.67 Grail, Inc.
  • 6.68 Grifols
  • 6.69 Guardant Health
  • 6.70 Guardiome
  • 6.71 HeiScreen
  • 6.72 Helix
  • 6.73 Helomics
  • 6.74 Hologic
  • 6.75 Horizon Discovery
  • 6.76 HTG Molecular Diagnostics
  • 6.77 Human Longevity, Inc.
  • 6.78 iCellate
  • 6.79 Illumina
  • 6.80 Incell Dx
  • 6.81 Inivata
  • 6.82 Invitae Corporation
  • 6.83 Invivoscribe
  • 6.84 Karius
  • 6.85 Macrogen
  • 6.86 MDNA Life SCIENCES, Inc.
  • 6.87 MDx Health
  • 6.88 Medgenome
  • 6.89 Meridian Bioscience
  • 6.90 Mesa Biotech
  • 6.91 MIODx
  • 6.92 miR Scientific
  • 6.93 MNG Labs
  • 6.94 Molecular MD
  • 6.95 NantHealth, Inc.
  • 6.96 Natera
  • 6.97 Nebula Genomics
  • 6.98 NeoGenomics
  • 6.99 New Oncology
  • 6.100 Novogene Bioinformatics Technology Co., Ltd.
  • 6.101 Omega Bioservices
  • 6.102 OncoDNA
  • 6.103 OpGen
  • 6.104 ORIG3N, Inc.
  • 6.105 Origene Technologies
  • 6.106 Oxford Nanopore Technologies
  • 6.107 Panagene
  • 6.108 Perkin Elmer
  • 6.109 Personal Genome Diagnostics
  • 6.110 Personalis
  • 6.111 Precipio
  • 6.112 PrecisionMed
  • 6.113 Promega
  • 6.114 Protagen Diagnostics
  • 6.115 Qiagen Gmbh
  • 6.116 Quantumdx
  • 6.117 Regeneron
  • 6.118 Roche Molecular Diagnostics
  • 6.119 Roswell Biotechnologies
  • 6.120 Seegene
  • 6.121 Sequencing.com
  • 6.122 Siemens Healthineers
  • 6.123 simfo GmbH
  • 6.124 Singlera Genomics Inc.
  • 6.125 SkylineDx
  • 6.126 Stratos Genomics
  • 6.127 Sure Genomics, Inc.
  • 6.128 Sysmex
  • 6.129 Sysmex Inostics
  • 6.130 Tempus Labs, Inc.
  • 6.131 Thermo Fisher Scientific Inc.
  • 6.132 Veritas Genetics
  • 6.133 Volition

7 The Global Market for Whole Genome Sequencing

  • 7.1 Global Market Overview by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country
  • 7.2 Global Market by Application - Overview
    • 7.2.1 Table - Global Market by Application
    • 7.2.2 Chart - Global Market by Application - Base/Final Year Comparison
    • 7.2.3 Chart - Global Market by Application - Base Year
    • 7.2.4 Chart - Global Market by Application - Final Year
    • 7.2.5 Chart - Global Market by Application - Share by Year
    • 7.2.6 Chart - Global Market by Application - Segment Growth
  • 7.3 Global Market by Organism - Overview
    • 7.3.1 Table - Global Market by Organism
    • 7.3.2 Chart - Global Market by Organism - Base/Final Year Comparison
    • 7.3.3 Chart - Global Market by Organism - Base Year
    • 7.3.4 Chart - Global Market by Organism - Final Year
    • 7.3.5 Chart - Global Market by Organism - Share by Year
    • 7.3.6 Chart - Global Market by Organism - Segment Growth
  • 7.4 Global Market by Product - Overview
    • 7.4.1 Table - Global Market by Product
    • 7.4.2 Chart - Global Market by Product - Base/Final Year Comparison
    • 7.4.3 Chart - Global Market by Product - Base Year
    • 7.4.4 Chart - Global Market by Product - Final Year
    • 7.4.5 Chart - Global Market by Product - Share by Year
    • 7.4.6 Chart - Global Market by Product - Segment Growth

8 Global Whole Genome Sequencing Markets - by Application

  • 8.1 Research
    • 8.1.1 Table Research - by Country
    • 8.1.2 Chart - Research Growth
  • 8.2 Clinical Human
    • 8.2.1 Table Clinical Human - by Country
    • 8.2.2 Chart - Clinical Human Growth
  • 8.3 Clinical Tumor
    • 8.3.1 Table Clinical Tumor - by Country
    • 8.3.2 Chart - Clinical Tumor Growth
  • 8.4 Clinical Pathogen
    • 8.4.1 Table Clinical Pathogen - by Country
    • 8.4.2 Chart - Clinical Pathogen Growth
  • 8.5 Direct to Consumer
    • 8.5.1 Table Direct to Consumer - by Country
    • 8.5.2 Chart - Direct to Consumer Growth
  • 8.6 Agriculture/Other
    • 8.6.1 Table Agriculture/Other - by Country
    • 8.6.2 Chart - Agriculture/Other Growth

9 Global Whole Genome Sequencing Markets - by Organism

  • 9.1 Human
    • 9.1.1 Table Human - by Country
    • 9.1.2 Chart - Human Growth
  • 9.2 Pathogen
    • 9.2.1 Table Pathogen - by Country
    • 9.2.2 Chart - Pathogen Growth
  • 9.3 Other Organism
    • 9.3.1 Table Other Organism - by Country
    • 9.3.2 Chart - Other Organism Growth

10 Global Whole Genome Sequencing Markets - by Product

  • 10.1 Instruments
    • 10.1.1 Table Instruments - by Country
    • 10.1.2 Chart - Instruments Growth
  • 10.2 Reagents
    • 10.2.1 Table Reagents - by Country
    • 10.2.2 Chart - Reagent Growth
  • 10.3 Analysis
    • 10.3.1 Table Analysis - by Country
    • 10.3.2 Chart - Analysis Growth
  • 10.4 Software & Other
    • 10.4.1 Table Software & Other - by Country
    • 10.4.2 Chart - Software & Other Growth

11 Vision of the Future of Whole Genome Sequencing

12 Appendices

  • 12.1 United States Medicare System: January 2021 laboratory Fees Schedule
  • 12.2 The Whole Genome Sequence of SARS-CoV-2
  • 12.3 Methodology
    • 12.3.1 Authors
    • 12.3.2 Sources

Table of Tables

  • Table 1 Leading Genomic Companies Revenue Growth (USD $M)
  • Table 2 The Base Pairs
  • Table 3 Most Common Traditional Genetic Disorders
  • Table 4 List of GLOBAL SEQUENCING LOCATIONS
  • Table 5 Market Players by Type
  • Table 6 The Different Markets for Whole Genome Sequencing
  • Table 7 DTC Sub Segments
  • Table 8 Roles of WGS in AgriBio
  • Table 9 The Factors Driving Growth
  • Table 10 Factors Limiting Growth
  • Table 11 - Listing of Current NGS Instrument Specifications
  • Table 12 Six New Sequencing Technologies
  • Table 13 - Global Market by Region
  • Table 14 Global Market by Application
  • Table 15 Global Market by Organism
  • Table 16 Global Market by Product
  • Table 17 Research by Country
  • Table 18 Clinical Human by Country
  • Table 19 Clinical Tumor by Country
  • Table 20 Clinical Pathogen by Country
  • Table 21 Direct to Consumer by Country
  • Table 22 Agriculture/Other by Country
  • Table 23 Human by Country
  • Table 24 Pathogen by Country
  • Table 25 Other Organism by Country
  • Table 26 Instruments by Country
  • Table 27 Reagents by Country
  • Table 28 Analysis by Country
  • Table 29 Software & Other by Country
  • Table 30 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Relative Growth of Select Genomic Companies
  • Figure 2 Size of Genome for Various Species
  • Figure 3 - Cost To Sequence a Human Genome
  • Figure 4 Base Year Country Market Share Chart
  • Figure 5 Global Market by Application - Base vs. Final Year
  • Figure 6 Global Market by Application Base Year
  • Figure 7 Global Market by Application Final Year
  • Figure 8 Application Type Share by Year
  • Figure 9 by Application Segment Growth
  • Figure 10 by Organism - Base vs. Final Year
  • Figure 11 by Organism Market Base Year
  • Figure 12 by Organism Market Final Year
  • Figure 13 by Organism Share by Year
  • Figure 14 by Organism Segment Growth
  • Figure 15 by Product - Base vs. Final Year
  • Figure 16 by Product Market Base Year
  • Figure 17 by Product Market Final Year
  • Figure 18 by Product Share by Year
  • Figure 19 by Product Segment Growth
  • Figure 20 Research Growth
  • Figure 21 Clinical Human Growth
  • Figure 22 Clinical Tumor Growth
  • Figure 23 Clinical Pathogen Growth
  • Figure 24 Direct to Consumer Growth
  • Figure 25 Agriculture/Other Growth
  • Figure 26 Human Growth
  • Figure 27 Pathogen Growth
  • Figure 28 Other Organism Growth
  • Figure 29 Instruments Growth
  • Figure 30 Reagent Growth
  • Figure 31 Analysis Growth
  • Figure 32 Software & Other Growth